Fairtility closes US$15m series A funding round for advanced clinical research

Fairtility, a company powering in vitro fertilisation (IVF) for improved outcomes, has announced the completion of a US$15m series A funding round.

Lacking objective and consistent methods for consolidating and interpreting end-to-end data from the embryology lab, IVF yields suboptimal and inconsistent outcomes. Yet, reproductive health professionals have been slow to adopt AI technologies more commonly used in other areas of healthcare, due in part to the lack of transparency in AI analysis.

Fairtility aims to change this by transforming AI-decision-making in IVF into a transparent process for both clinicians and patients with CHLOE EQ™ (Cultivating Human Life through Optimal Embryos) – the company’s embryo quality assessment assistant.

CHLOE EQ™ provides visibility into the biological data that informs the system’s embryo assessment conclusions. Its data output is intended to support IVF professionals’ experience and intuition, augmenting decision-making with the collective analysis of millions of data points collected from a diverse set of embryology labs and workflows globally.

Powering IVF professionals with this data facilitates improved decision-making and informative conversations with patients with the goal of reducing the number of IVF cycles to live birth and improving patient care.

The recent funding round was led by Boston-based, Gurnet Point Capital, and included Nacre Capital and other additional investors.

Fairtility is planning to invest the resources from its series A funding round into advanced clinical research with fertility clinics and marquee academic institutions globally, as well as in regulatory approval processes while continuing to develop CHLOE™ beyond embryo assessment.

“Despite advancements in fertility treatments, IVF still only averages a 30 percent success rate per treatment cycle,” explains Eran Eshed, co-founder and CEO of Fairtility. “We are excited to partner with such prominent investors that are helping us realise our vision of enhancing IVF outcomes and efficiency through digitisation.

“We believe that the transparency and user-centricity of our platform will significantly improve workflow efficiency, and data-driven decision-making for better IVF outcomes. This will make IVF more accessible to a larger population of people contending with infertility.”

Sophie Kornowski, senior partner at Gurnet Point Capitals says that: “We are truly excited to partner with Fairtility, as they connect state of the art technology to improve women’s health and provide better infertility care for those desiring a family. After a long and thorough diligence process, we believe that Fairtility has the best in technology and ability to execute on our shared vision.”

Howard Morgan, chairman of Nacre Capital points out that: “IVF is a field of medicine that is primed for AI adoption, yet current solutions remain limited in their scope. IVF professionals are not given access to data that explains AI outputs; clinicians today are asked to ‘trust’ the system.

“Fairtility’s approach is above the rest technologically with all the ingredients needed to create profound transformation in this market – world class data-scientists, fertility specialists and no less important, an experienced leadership team which has built numerous successful companies.”

For more info, visit fairtility.com.